Literature DB >> 17345788

Clinical characteristics of aldosterone-producing microadenoma, macroadenoma, and idiopathic hyperaldosteronism in 93 patients with primary aldosteronism.

Masao Omura1, Hironobu Sasano, Jun Saito, Kunio Yamaguchi, Yukio Kakuta, Tetsuo Nishikawa.   

Abstract

Primary aldosteronism (PA) due to aldosterone-producing adenoma (APA) is a form of surgically curable secondary hypertension, and distinguishing APA from idiopathic hyperaldosteronism (IHA) is important for treatment. We made a differential diagnosis between APA and IHA using imaging tests such as adrenal CT and MRI as well as adrenal venous sampling (AVS) in all 93 cases of PA presenting at our institutions over the last decade. We identified 27 patients with aldosterone-producing microadenoma (APmicroA), all of whom could be diagnosed by AVS but not by the imaging tests. Then, we compared the clinical and roent-genological findings of these 27 patients with those of 42 patients with aldosterone-producing macroadenoma (APmacroA) and of 24 patients with IHA. Using surgically removed adrenal tissues, histopathological examinations and immunohistochemical analyses of steroidogenic enzymes were conducted. The findings for APmicroA were similar to those for APmacroA, except with respect to the diameter of the adrenal adenomas. Endocrinological and roentgenological findings for APmicroA were similar to those for IHA, but not to those for APmacroA. The rate of cure of hypertension was much greater in patients with APmicroA than in patients with APmacroA after the unilateral adrenalectomy (odds ratio, 4.0; p=0.028). In conclusion, it is important to accurately diagnose APmicroA, in which the laterality of the hyperproduction of aldosterone is only detectable by AVS, and to treat these patients by unilateral adrenalectomy in order to avoid long-term medical treatment and prevent hypertensive vascular complications.

Entities:  

Mesh:

Year:  2006        PMID: 17345788     DOI: 10.1291/hypres.29.883

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  31 in total

1.  Primary aldosteronism and hypercortisolism due to bilateral functioning adrenocortical adenomas.

Authors:  Kenji Oki; Kiminori Yamane; Yu Sakashita; Nozomu Kamei; Hiroshi Watanabe; Naoyuki Toyota; Masanobu Shigeta; Hironobu Sasano; Nobuoki Kohno
Journal:  Clin Exp Nephrol       Date:  2008-06-10       Impact factor: 2.801

2.  Historical changes and between-facility differences in adrenal venous sampling for primary aldosteronism in Japan.

Authors:  Yuichi Fujii; Yoshiyu Takeda; Isao Kurihara; Hiroshi Itoh; Takuyuki Katabami; Takamasa Ichijo; Norio Wada; Yui Shibayama; Takanobu Yoshimoto; Yoshihiro Ogawa; Junji Kawashima; Masakatsu Sone; Nobuya Inagaki; Katsutoshi Takahashi; Minemori Watanabe; Yuichi Matsuda; Hiroki Kobayashi; Hirotaka Shibata; Kohei Kamemura; Michio Otsuki; Koichi Yamamto; Atsushi Ogo; Toshihiko Yanase; Shintaro Okamura; Shozo Miyauchi; Megumi Fujita; Tomoko Suzuki; Hironobu Umakoshi; Tatsuki Ogasawara; Mika Tsuiki; Mitsuhide Naruse
Journal:  J Hum Hypertens       Date:  2019-08-28       Impact factor: 3.012

3.  Histopathological Classification of Cross-Sectional Image-Negative Hyperaldosteronism.

Authors:  Yuto Yamazaki; Yasuhiro Nakamura; Kei Omata; Kazue Ise; Yuta Tezuka; Yoshikiyo Ono; Ryo Morimoto; Yukinaga Nozawa; Celso E Gomez-Sanchez; Scott A Tomlins; William E Rainey; Sadayoshi Ito; Fumitoshi Satoh; Hironobu Sasano
Journal:  J Clin Endocrinol Metab       Date:  2017-04-01       Impact factor: 5.958

4.  Different expression of 11β-hydroxylase and aldosterone synthase between aldosterone-producing microadenomas and macroadenomas.

Authors:  Yoshikiyo Ono; Yasuhiro Nakamura; Takashi Maekawa; Saulo J A Felizola; Ryo Morimoto; Yoshitsugu Iwakura; Masataka Kudo; Kazumasa Seiji; Kei Takase; Yoichi Arai; Celso E Gomez-Sanchez; Sadayoshi Ito; Hironobu Sasano; Fumitoshi Satoh
Journal:  Hypertension       Date:  2014-05-19       Impact factor: 10.190

5.  Significance of adrenal computed tomography in predicting laterality and indicating adrenal vein sampling in primary aldosteronism.

Authors:  K Kamemura; N Wada; T Ichijo; Y Matsuda; Y Fujii; T Kai; T Fukuoka; R Sakamoto; A Ogo; T Suzuki; H Umakoshi; M Tsuiki; M Naruse
Journal:  J Hum Hypertens       Date:  2016-09-01       Impact factor: 3.012

6.  Hypertension Cure Following Laparoscopic Adrenalectomy for Hyperaldosteronism is not Universal: Trends Over Two Decades.

Authors:  Takeshi Namekawa; Takanobu Utsumi; Tomoaki Tanaka; Mayuko Kaga; Hidekazu Nagano; Takashi Kono; Koji Kawamura; Naoto Kamiya; Takashi Imamoto; Hiroyoshi Suzuki; Tomohiko Ichikawa
Journal:  World J Surg       Date:  2017-04       Impact factor: 3.352

7.  Cosyntropin stimulation in adrenal vein sampling improves the judgment of successful adrenal vein catheterization and outcome prediction for primary aldosteronism.

Authors:  Midori Yatabe; Kanako Bokuda; Kaoru Yamashita; Satoshi Morimoto; Junichi Yatabe; Yasufumi Seki; Daisuke Watanabe; Satoru Morita; Shuji Sakai; Atsuhiro Ichihara
Journal:  Hypertens Res       Date:  2020-04-30       Impact factor: 3.872

8.  Kidney dysfunction following adrenalectomy in autosomal dominant polycystic kidney disease complicated with primary aldosteronism: A case report.

Authors:  Hiroyuki Hirai; Makoto Kanno; Tsuyoshi Watanabe; Hiroaki Satoh
Journal:  Exp Ther Med       Date:  2017-06-13       Impact factor: 2.447

Review 9.  Primary aldosteronism, diagnosis and treatment in Japan.

Authors:  Yoshiyu Takeda; Shigehoro Karashima; Takashi Yoneda
Journal:  Rev Endocr Metab Disord       Date:  2011-03       Impact factor: 6.514

10.  18-oxocortisol measurement in adrenal vein sampling as a biomarker for subclassifying primary aldosteronism.

Authors:  Yasuhiro Nakamura; Fumitoshi Satoh; Ryo Morimoto; Masataka Kudo; Kei Takase; Celso E Gomez-Sanchez; Seijiro Honma; Mitsunobu Okuyama; Kouwa Yamashita; William E Rainey; Hironobu Sasano; Sadayoshi Ito
Journal:  J Clin Endocrinol Metab       Date:  2011-05-18       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.